AstraZeneca's Forxiga nabs expanded heart failure approval in Europe

AstraZeneca’s SGLT2 diabetes drug Forxiga has another approval to celebrate.

The drug, known as Farxiga in the U.S., gained a nod in Europe to treat patients suffering from heart failure with any type of left ventricular ejection fraction, including mildly reduced and preserved.